Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses available treatments for androgenetic alopecia and highlights that, although no definitive treatment exists, current options generally achieve high satisfaction rates.

This study reviews hair follicle physiology and common scalp diseases such as androgenetic alopecia, telogen effluvium, and alopecia areata, highlighting their pathophysiology and current treatment approaches, which may include topical, systemic, and adjunctive therapies.

This study reported that among individuals with long COVID, hematologic disturbances such as inflammation-related anemia, characterized by high hepcidin levels and restricted iron use, were prevalent, contributing to reduced capacity, fatigue, and slow recovery, especially in men and those with severe acute COVID-19.

This study reviewed interventions for post-COVID-19 alopecia and concluded that integrated physiotherapeutic strategies, including photobiomodulation, micro-needling, electrotherapy, and scalp massage, can reduce hair loss and improve hair density, contributing positively to patient quality of life.

This integrative literature review found that hydroxychloroquine may stabilize inflammatory scarring autoimmune alopecias like frontal fibrosing alopecia, especially when combined with other therapies, while its effectiveness in non-scarring alopecias appears inconsistent and is limited to refractory cases.

This integrative review found that triamcinolone hexacetonide remains the primary treatment for mild to moderate alopecia areata but noted its significant side effects with prolonged use, while emerging therapies like PRP and minoxidil offer promising alternative benefits with fewer risks.

In this study, a literature review concluded that minoxidil is safe and effective for treating androgenetic alopecia, with few side effects, and highlighted the role of pharmacists in optimizing treatment by monitoring use and fostering adherence.

Low-dose oral minoxidil is effective and generally safe for treating hair loss in women.

This study explored the connections between Covid-19 and hair loss issues like telogen effluvium and alopecia areata, highlighting the virus's potential trigger effect and underscoring the importance of comprehensive post-Covid-19 treatment strategies that consider immune, psychological, and hair cycle factors.

This review reports various ethnomedicinal uses, phytochemical components, and potential pharmacological effects of Eclipta alba, highlighting benefits like wound healing and neuroprotection, though it underscores the need for further mechanism-based studies and clinical trials.

This summary of a pharmacy internship reports on expanding scientific knowledge through diverse activities, including exploring diabetes medications for obesity treatment and discussing the role of nutritional supplements in geriatrics.

This systematic review found that anxiety disorders are significantly more prevalent among patients with various psychodermatoses compared to the general population.

This article discusses the organizational aspects of the II National Academic Congress of Dermatology in Brazil and reports no new research findings.

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.

This study found that the ethanolic extract of Guazuma ulmifolia, or mutamba, showed only intermediate levels of phenolic compounds and low antioxidant activity in laboratory tests, suggesting limited potential in alleviating oxidative stress conditions like cancer or cardiovascular diseases.

This review covers current knowledge of tricoscopy's applications in diagnosing and monitoring scalp and hair disorders but presents no new clinical results.

This report details the case of an 11-year-old girl with APECED syndrome carrying a unique homozygous mutation in the AIRE gene, the first of its kind documented.

This study demonstrated that AIRE-deficient rats exhibit key symptoms of APECED, making them a relevant model for exploring potential treatments.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.

This study found that AIRE, a usually nuclear protein, is expressed in the cytoplasm of human epidermal and follicular keratinocytes and associates with the intermediate filament protein cytokeratin 17, potentially impacting ectodermal abnormalities in APECED syndrome.

This study in a nine-year-old boy from Lebanon identified a gene mutation (c.1066dup p.(Arg356Profs*16)) associated with a rare inborn error of immunity, characterized by craniosynostosis, jaundice, and several other symptoms, expanding the known genotypic and phenotypic spectrum of this condition.

This study identified four novel and one recurrent mutation in the AIRE gene among Arab families with APS1, suggesting these contribute to the disorder.

This study found that Aire‒/‒ mice spontaneously developed persistent AA-like lesions, highlighting a potential role for AIRE in hair follicle biology and pathogenesis of alopecia areata.

In this study, researchers found that the AIRE G961C variant is a significant risk factor for severe alopecia areata and early-onset cases, particularly in patients with alopecia universalis.

This report reviews the clinical presentation and genetic aspects of a case of acrodermatitis enteropathica in a one-year-old child but provides no new clinical findings.

This study developed an in vitro model using NTERT keratinocytes expressing AEC-related TP63 mutations, which replicated skin defects observed in AEC patients and offers a valuable tool for understanding the disorder and developing new treatments.

In a mouse model study, researchers found that mutations in Aire reduced alopecia areata frequency, while Notch4 mutations did not lead to the disease, likely due to proximity with a resistance gene.

In this study, the rs4541843 G > A variant was found to be significantly associated with increased risk and severity of alopecia areata, as well as elevated expression of hsa-miR-182-5p, suggesting their potential as molecular markers for diagnosis and severity assessment.

A child on life support experienced rapid hair loss due to severe illness affecting hair growth.

This study found that alefacept showed no significant improvement in treating severe alopecia areata compared to placebo over a 24-week period.